Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
about
A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosisManaging Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersInteraction of obesity and inflammatory bowel diseasePsoriasis and comorbid diseases: Implications for management.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Methotrexate hepatotoxicity in patients with rheumatoid arthritis.Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymesSystems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the ratIncreased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis.Secondary causes of nonalcoholic fatty liver disease.Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment.Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent.Histological assessment of non-alcoholic fatty liver disease.Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasisObesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review.Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C.Psoriasis and non-alcoholic fatty liver disease.The use of methotrexate in dermatology: a review.The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies.Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance.A review of methotrexate-associated hepatotoxicity.Application of urine proteomics for biomarker discovery in drug-induced liver injury.Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain.Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors.Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role?Deficiency of the Mitochondrial NAD Kinase Causes Stress-induced Hepatic Steatosis in Mice.Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography.Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment
P2860
Q24813770-57D89F67-3824-4E0E-9423-2B23F7C9B9BAQ26771785-9911FAFF-F9CC-4284-875F-B300C6537EA1Q28072225-23E606BA-6925-4677-8AFC-5367A91A8ABFQ30235888-870A45FB-33EC-403A-B659-7E1520E199F7Q33654733-D70A6D98-8CC9-4CBF-BE84-80A02ED6C901Q34134484-A092A9C8-EB1E-484F-83AC-ABBEFF015FF7Q34153004-720BEDDC-DB57-4964-9A79-8AD02B9866B8Q34483949-2DE1F3F0-39A3-4016-AEEC-7B9F660ABBCFQ35102604-9060DA1B-5746-470E-AFDD-3D30EEC3436FQ35444953-51479757-0A93-489F-AFE7-92AC3826ED86Q35929072-B50451FF-0835-40AB-9EB2-044BE5C1DFD9Q36036715-83D30F52-4202-4259-8B25-0F333AC58A38Q36570815-70377795-ACAF-4ED9-87BE-7E2E714837CEQ36634377-E58D0E3B-DB6F-4F88-8B01-189981030508Q36876383-4CFEB19F-F484-48EF-8DDA-B397A260EEAAQ36879686-D357AB76-2112-42FC-ACDA-14B3F88E07E9Q37243485-8A1B715D-5726-4777-8954-12C173B49F10Q37788777-0986AD62-3BD1-4279-9903-3C26942CC33DQ37981730-00571C30-26A4-440F-B707-21AD83A84419Q38010769-EF7BB6FA-C4A3-471C-90AB-420F8F44B8DBQ38098466-97F7DDAC-4111-4FD7-813C-B2F927BE961BQ38194199-FC9E5933-D130-4134-91BB-721721D3EF06Q38237705-4454C6A8-3B13-4751-A99E-5ACB52B396A6Q38241492-1E228ACF-961B-44E1-8EEB-52A22299D5E4Q38255178-D267E3A2-0852-44FD-96F6-74830E6A617FQ38687132-3700099B-CE14-4DDD-972A-110E3131A403Q38737633-E1939D9B-D952-4ADC-A0BB-E8F00D34AF9DQ39227956-77BD886C-23DC-4199-AAA5-9BB7D52ADC12Q39735574-26501471-A15F-4BE3-8C28-134D2A26924AQ40837256-B068228A-D8DB-401A-B9E0-39B845B041A3Q46304887-FD11F29D-6480-479F-9B69-4EE49F2E5DC1Q46375268-9E23C2A1-52A2-46C8-89E4-442DF2004AF1Q46699120-1F0D4327-8B5F-4FD4-A227-17F29A1C16F9Q55082101-6F78EF24-4AA2-4B9F-9B9B-137D38186921Q58708624-97505AEF-8A12-4EB0-9865-D5297E61FAA4
P2860
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@en
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@nl
type
label
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@en
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@nl
prefLabel
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@en
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@nl
P2093
P2860
P1476
Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
@en
P2093
P2860
P304
P356
10.1046/J.1440-1746.2001.02644.X
P577
2001-12-01T00:00:00Z